ClinicalTrials.gg
Status unknownNCT03394001Updated Jan 9, 2018

Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy

A Phase 4 interventional study of Wound infiltration and Lidocaine Hydrochloride in Anesthesia, sponsored by Ain Shams University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-01-09.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
Female
01

Study summary

The main goal of this study is to compare wound infiltration with ketorolac versus lidocaine for postoperative analgesia in total abdominal hystrectomy (TAH) operation.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I and II
  • Planned for elective TAH with a Pfannenstiel incision

Exclusion criteria

Exclusion Criteria:

Patients with the following criteria will be excluded from the study;

  • more than II
  • (BMI)>35 kg/m2
  • Previous abdominal surgeries
  • Individuals with chronic pain
  • A history of severe systemic disease
  • A pre-existing neurological or psychiatric illness
  • Known to be addict on alcohol or drugs
  • Known allergy to the study drugs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Lidocaine Hydrochloride

    Wound infiltration with Lidocaine

    Procedure: Wound infiltration · Drug: Lidocaine Hydrochloride

  • Active comparator
    Ketorolac tromethamine

    Wound infiltration with Ketorolac

    Procedure: Wound infiltration · Drug: Ketorolac tromethamine

Interventions

  • ProcedureWound infiltration

    Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.

  • 20 ml of 1% Lidocaine solution

    Also known as: Lidocaine Hydrochloride; Lidocaine HCL 50mg/5 ml

  • 20 mL of saline with 30 mg ketorolac

    Also known as: Adolor; Ketorolac tromethamine 30mg/2ml

06

What researchers measure

Primary outcomes

  1. Rescue analgesia time

    Time for first analgesia requirement

    Time frame: First 24 hours postoperatively

Secondary outcomes

  1. Patient's pain score

    Pain score will be done by visual analog scale (VAS) (minimum 0 = no pain, while maximum 10 cm = worst possible pain). Pain score will be recorded just after extubation (taken as 0 h) and after 1, 2, 4, 6, 12, 18 and 24 h later. Patients will be instructed about the usage of VAS scalebefore the operation.

    Time frame: First 24 hours postoperatively

  2. The total analgesic consumption

    Postoperative analgesia will be provided with intramuscular (IM) meperidine 50 mg to both groups when the VAS score is ≥4. The total meperidine consumption will be recorded.

    Time frame: First 24 hours postoperatively

07

Study locations

1 site
  • Ain Shams University hospitals
    Cairo, 11591, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Jun 2018, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Jan 9, 2018
StartActual
Jan 1, 2018
Primary completionEst.
Jun 2018
CompletionEst.
Jun 2018
Last update
Jan 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03394001
Responsible party
Marwa Mostafa Mohamed Ali Mowafi (Lecturer, Ain Shams University) — Principal investigator
First posted
Jan 9, 2018
Start date
Jan 1, 2018
Primary completion
Jun 2018 (estimated)
Completion
Jun 2018 (estimated)
Last update
Jan 9, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Ketorolac Tromethamine

Start the discussion